Last reviewed · How we verify
Valsartan (Diovan)
Valsartan blocks angiotensin II receptors on blood vessels and the heart, causing vasodilation and reducing blood pressure.
Valsartan blocks angiotensin II receptors on blood vessels and the heart, causing vasodilation and reducing blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction with left ventricular dysfunction.
At a glance
| Generic name | Valsartan (Diovan) |
|---|---|
| Sponsor | Radboud University Medical Center |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor subtype. By blocking angiotensin II—a potent vasoconstrictor and aldosterone-stimulating hormone—valsartan reduces peripheral vascular resistance, lowers blood pressure, and decreases cardiac workload. This mechanism also provides cardioprotective and renoprotective effects in heart failure and hypertension.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction with left ventricular dysfunction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Diarrhea
- Headache
Key clinical trials
- Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy (NA)
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (PHASE1, PHASE2)
- A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
- A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction (PHASE1)
- A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
- The ENCHANTMENT HIV Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan (Diovan) CI brief — competitive landscape report
- Valsartan (Diovan) updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI